Stay updated with breaking news from Jenifer Antonacci. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Results from the Phase 2 L-MIND study were highlighted as a late-breaking oral presentation at the American Association for Cancer Research Annual Meeting 2023 MorphoSys U.S. Inc., a fully owned subsidiary
-This marks the second indication for Pemazyre, which received accelerated FDA approval in 2020 for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with
Press release content from Business Wire. The AP news staff was not involved in its creation.
DGAP-News: MorphoSys AG / Key word: Agreement/Miscellaneous Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi® in Combination with TTI-622, a Fusion... | June 13, 2022
DGAP-News: MorphoSys AG / Key word(s): Agreement/MiscellaneousPfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi® (tafasitamab-cxix) in Combination with TTI-622, a Fusion Protein Directed Against CD47 13.06.2022 / 22:01 The issuer is solely responsible for the content of this announceme...